A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients

NCT06857955 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

380

Enrollment

INDUSTRY

Sponsor class

Conditions

Hypertension

Interventions

OTHER: Saline
DRUG: QCZ484

Sponsor

Novartis Pharmaceuticals